(Q44518870)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12871443%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

title

Thalidomide and thrombosis in multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12871443%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

0 references

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12871443%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

author name string

Barbui T

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12871443%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

publication date

1 March 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12871443%20AND%20SRC:MED&resulttype=core&format=json

Journal of Thrombosis and Haemostasis

6 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12871443%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12871443%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12871443%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

page(s)

421-422

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12871443%20AND%20SRC:MED&resulttype=core&format=json

Antitumor activity of thalidomide in refractory multiple myeloma

6 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00084.X

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00084.X

Thalidomide in the management of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00084.X

Deep venous thrombosis and thalidomide therapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00084.X

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00084.X

Thromboembolic events during treatment with thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00084.X

Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00084.X

Pathophysiology of the thrombophilic state in the cancer patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00084.X

Coagulopathy of acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00084.X

Epidemiology of thrombosis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00084.X